VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MDTMedtronic plc
$80.98$104.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMDTCash Flow

Medtronic plc (MDT) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow remains highly volatile, swinging from a 5.1% margin in 2026Q2 to 21.3% in 2026Q4, while the firm continues to prioritize shareholder returns through consistent $900M quarterly dividend payments.

MDT Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricApr'26Apr'25Apr'24Apr'23Apr'22Apr'21Apr'20Apr'19Apr'18Apr'17Apr'16Apr'15Apr'14Apr'13Apr'12Apr'11Apr'10Apr'09Apr'08Apr'07Apr'06Apr'05Apr'04Apr'03Apr'02Apr'01Apr'00Apr'99Apr'98Apr'97
Cash from Operations7.33B7.04B6.79B6.04B7.35B6.24B7.23B7.01B4.68B6.88B5.22B4.9B4.96B4.88B4.47B3.74B4.13B3.88B3.49B2.98B2.21B2.82B2.85B2.08B1.59B1.83B1.04B455.3M693.1M463.6M
Operating CF Margin %20.16%21%20.97%19.34%23.18%20.72%25.02%22.93%15.64%23.16%18.1%24.19%29.16%29.43%27.62%23.48%26.12%26.56%25.82%24.22%19.55%28.04%31.32%27.11%24.8%32.99%20.78%11.01%26.61%19.01%
Operating CF Growth %4.06%3.79%12.39%-17.79%17.72%-13.74%3.24%49.59%-31.92%31.85%6.45%-1.15%1.56%9.24%19.49%-9.44%6.52%11.15%17.12%34.96%-21.71%-0.93%36.94%30.69%-13.18%75.77%128.86%-34.31%49.5%-7.37%
Net Income4.84B4.69B3.68B3.78B5.06B3.63B4.81B4.65B3.1B4.02B3.54B2.67B3.06B3.47B3.62B3.1B3.1B2.17B2.23B2.8B2.55B1.8B1.96B1.6B984M1.05B1.1B468.4M594.6M530M
Depreciation & Amortization2.96B2.86B2.65B2.7B2.71B2.7B2.66B2.66B2.64B2.92B2.82B1.31B850M819M862M804M772M699M637M583M543.6M463.3M442.6M408.1M329.8M297.3M243.3M213.1M166.5M116.9M
Stock-Based Compensation457M429M393M355M359M344M297M290M344M348M376M439M145M152M161M198M226M237M217M00000000000
Deferred Taxes51M-316M-508M-226M-604M-422M-1.31B-304M-919M-459M-460M-926M-207M60M14M153M144M-116M-49M-236M104.7M-142.5M110.5M202.6M50.9M-152.2M71.1M-35.9M21.5M2M
Other Non-Cash Items450M433M1.06B396M711M687M722M792M-307M-89M34M-156M888M151M-84M502M214M620M459M278M502M715.2M91.7M104.5M536.2M317.1M8.5M177.3M125.5M0
Working Capital Changes-1.42B-1.05B-484M-967M-889M-701M61M-1.08B-173M139M-1.09B1.56B218M234M-100M-1.01B-324M269M-6M-448M-1.49B-20.5M241.7M-236.8M-310.7M323.3M-379.4M-367.6M-115.3M-185.3M
Change in Receivables-200M-433M-391M-576M-477M-761M1.29B-581M-275M-75M-435M-413M-70M1M-252M-342M-271M108M-461M-326M-216.6M-227.7M-171.5M-139.9M-188.9M-44.1M0000
Change in Inventory-404M-292M-139M-939M-560M78M-577M-274M-192M-227M-186M-282M-39M93M-185M-101M158M-212M30M-24M-257.1M-51.3M127.6M-91.7M30.4M-44.5M-119.1M-86.7M-59.8M-16.9M
Change in Payables46M209M391M696M213M531M-44M399M65M356M-65M1.62B-117M422M182M-37M257M399M61M17M-968.3M423.2M00000000
Cash from Investing-2.93B-1.94B-2.37B-3.49B-1.66B-2.87B-3.2B-774M5.86B-1.57B2.25B-17.06B-3.59B-3.05B-2.65B-1.81B-4.76B-2.74B-2.79B-1.7B-2.87B-1.6B-1.65B-249.6M-4.38B-1.03B-376.6M-1.31B-173.8M78M
Capital Expenditures-1.9B-1.86B-1.59B-1.46B-1.37B-1.35B-1.21B-1.13B-1.07B-1.25B-1.05B-571M-396M-457M-528M-548M-635M-663M-606M-694M-1.24B-452M-424.6M-380.4M-386.4M-439.7M-342.1M-1.24B-148.2M-190.2M
CapEx % of Revenue5.24%5.54%4.9%4.67%4.32%4.5%4.2%3.71%3.57%4.22%3.63%2.82%2.33%2.75%3.26%3.44%4.01%4.54%4.48%5.64%11.02%4.5%4.67%4.96%6.03%7.92%6.82%30.09%5.69%7.8%
Acquisitions-406M-98M-211M-1.87B-91M-994M-488M-1.83B5.92B-1.32B-1.21B-14.88B-385M-820M-617M-1.33B-350M-1.62B-4.22B-8M-285.2M-107.9M-30.9M-1.9M-4.06B00000
Investments------------------------------
Other Investing-4M-249M-261M4M-10M-54M-37M36M-22M22M-14M89M-29M-14M470M-129M-87M-338M-87M-56M100.5M-45.2M15.5M3.7M-157.7M-118.8M-45M-30.7M-42.3M-99.1M
Cash from Financing-4.75B-4.36B-4.45B-4.96B-5.34B-4.14B-4.2B-5.43B-11.95B-3.28B-9.54B15.95B-918M-2.1B-1.88B-2.01B764M-845M-835M-3.01B1.32B-488.8M-1.01B-743.8M2.17B-245.7M-426M604.8M-125.7M-363.1M
Debt Issued (Net)-1.17B2.14B1.07B-598M-1M-570M-559M-867M-7.6B2.18B-5.13B18.67B1.43B-26M601M18M2.54B317M831M-1.83B5.41B88M-19.5M-177M2.35B-153.7M50M71.1M-39.2M70.8M
Equity Issued (Net)-519M-2.73B-1.85B-645M-2.12B-652M-1.33B-1.89B-1.77B-3.12B-2.34B-1.27B-2.55B-980M-1.34B-1.05B-865M-343M-1.14B-708M-3.07B-172M-639.1M-262.6M94.9M148.7M-286.5M665.6M12.3M-343.2M
Dividends Paid-3.64B-3.59B-3.67B-3.62B-3.38B-3.12B-2.89B-2.69B-2.49B-2.38B-2.14B-1.34B-1.12B-1.05B-1.02B-969M-907M-843M-565M-504M-464.8M-404.9M-351.5M-304.2M-278.8M-240.7M-189.5M-131.9M-102.9M-90.7M
Share Repurchases-1.03B-3.23B-2.14B-645M-2.54B-652M-1.33B-2.88B-2.17B-3.54B-2.83B-1.92B-2.55B-1.25B-1.44B-1.14B-1.03B-759M-1.54B-1.04B-4.66B-511M-880.5M-418.5M-25.6M0-497.4M-377.2M-168.2M-476.6M
Other Financing582M-184M-3M-101M163M206M581M14M-94M26M60M-116M1.32B-40M-118M0024M40M36M-557.8M100K0000004.1M0
Net Change in Cash-269M934M-259M-2.17B121M-547M-253M724M-1.3B2.09B-1.97B3.44B484M-264M-134M-18M129M211M-196M-1.74B762.1M638.5M123.6M1.06B-619.6M562.5M219.9M-297.4M185.4M46.3M
Free Cash Flow5.43B5.18B5.2B4.58B5.98B4.88B6.02B5.87B3.62B5.63B4.17B4.33B4.56B4.43B3.85B3.19B3.5B3.21B2.88B2.29B963.2M2.37B2.42B1.7B1.2B1.39B699.9M-788.5M441.9M273.4M
FCF Margin %14.92%15.46%16.07%14.67%18.87%16.22%20.82%19.22%12.07%18.94%14.47%21.38%26.83%26.68%23.81%20.04%22.1%22.02%21.33%18.58%8.53%23.55%26.64%22.15%18.78%25.07%13.96%-19.07%16.96%11.21%
FCF Growth %4.65%-0.29%13.54%-23.39%22.37%-18.87%2.52%62.42%-35.73%34.85%-3.67%-5.08%3.1%14.87%20.67%-8.67%8.74%11.52%26.17%137.23%-59.31%-2.22%42.61%41.04%-13.51%98.86%188.76%-278.43%61.63%-18.8%
FCF per Share4.214.023.913.444.423.614.464.332.644.042.933.914.504.313.642.953.152.852.521.970.791.941.981.380.981.140.57-0.650.380.23
FCF Conversion (FCF/Net Income)1.53x1.51x1.85x1.61x1.46x1.73x1.51x1.51x1.51x1.71x1.47x1.83x1.62x1.41x1.24x1.21x1.33x1.79x1.56x1.06x0.87x1.56x1.45x1.30x1.62x1.75x0.95x0.97x1.17x0.79x
Interest Paid774M762M826M606M540M582M643M973M1.15B1.13B1.27B578M394M333M312M292M386M208M258M00000000000
Taxes Paid1.94B1.82B1.62B1.55B996M1.25B878M1.56B2.54B1.03B1.38B632M521M537M454M826M571M436M717M00000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Working capital volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Earnings Quality and Cash Divergence

As reported in recent financial filings, Medtronic's OCF/NI ratio has fluctuated significantly, ranging from a low of 0.67 in 2026Q2 to a high of 4.25 in 2024Q4, indicating that net income is an unreliable proxy for the firm's actual cash-generating capacity on a quarterly basis.

The wide variance between net income and operating cash flow suggests that non-cash items and working capital swings heavily influence reported earnings. Investors should monitor whether this volatility reflects genuine operational friction or merely the timing of large-scale enterprise contract settlements.

FCF Margin Volatility Remains High

Based on the provided cash flow data, free cash flow margins have exhibited extreme instability, swinging from a low of 5.1% in 2026Q2 to a peak of 27.4% in 2024Q4, which complicates the assessment of the company's long-term cash generation trajectory.

This erratic FCF performance appears to be driven by lumpy working capital requirements rather than structural changes in profitability. The inconsistency in cash conversion suggests that the company's ability to fund dividends and buybacks is subject to significant quarterly timing risks.

Working Capital Swings Obscure Performance

According to the quarterly cash flow statements, working capital changes have been highly erratic, oscillating between a $1.4B outflow in 2026Q2 and a $924M inflow in 2024Q4, which suggests significant variability in the company's inventory management and accounts receivable collection cycles.

These dramatic shifts in working capital appear to be the primary driver of the company's inconsistent cash flow profile. Analysts should investigate whether these swings are indicative of seasonal hospital procurement patterns or potential inefficiencies in the supply chain management of high-acuity medical devices.

Capital Allocation Prioritizes Shareholder Returns

As evidenced by the reported figures, Medtronic consistently allocates substantial cash to dividends, totaling approximately $900M per quarter, while share repurchases have been more opportunistic, peaking at $2.5B in 2025Q1, suggesting a management focus on returning capital despite volatile operating cash flow.

The commitment to a steady dividend payout appears to be a core pillar of the company's capital allocation strategy, even during periods of lower cash generation. However, the reliance on debt or cash reserves to maintain these payouts during low-FCF quarters warrants further investigation into the sustainability of this policy.

MDT — Frequently Asked Questions

Quick answers to the most common questions about buying MDT stock.

How much cash does Medtronic plc (MDT) generate from operations?

Medtronic plc (MDT) generated $7.33B in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.

What is Medtronic plc's free cash flow?

Medtronic plc (MDT) generated $5.43B in free cash flow in 2026. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Medtronic plc's capital expenditure (CapEx)?

Medtronic plc (MDT) spent $1.90B on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Medtronic plc distribute cash to shareholders?

In 2026, Medtronic plc (MDT) returned $3.64B to shareholders via cash dividends and spent $1.03B on share repurchases. This shows the company's commitment to returning capital to its equity investors.